Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective—A report by Polish Myeloma Study Group.

Highlights: [•] Bortezomib-based regimens were evaluated in 708 relapsed/refractory myeloma pts. [•] The ORR was 67.9% for refractory and 69.9% for relapsed MM. [•] The median PFS was 14 months and OS 57 months. [•] Patients responding to the therapy had the probability of a 4-year OS at 67.0%. [•] Toxicity after bortezomib-based treatment was predictable and manageable. [Copyright &y& Elsevier]